Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:54 AM
Ignite Modification Date:
2025-12-25 @ 4:54 AM
NCT ID:
NCT00376818
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed malignant brain tumor of 1 of the following subtypes:
* Anaplastic astrocytoma
* Glioblastoma multiforme
* Astrocytoma WHO grade IV
* Malignant meningioma
* Anaplastic oligodendroglioma
* Anaplastic oligoastrocytoma
* Gliosarcoma
* Anaplastic ependymoma
* Medulloblastoma
* Caregivers must meet the following criteria:
* Primary family caregiver
* Age 18 and over
PATIENT CHARACTERISTICS:
* Karnofsky performance status 70-100%\*
* Absolute neutrophil count ≥ 1,500/mm³\*
* Platelet count ≥ 100,000/mm³\*
* Bilirubin ≤ 2 times normal\*
* Alkaline phosphatase ≤ 2 times normal\*
* SGOT ≤ 3 times normal\*
* BUN or creatinine ≤ 1.5 times normal\*
* No other prior (within the past 3 years) or concurrent malignancies except for surgically cured carcinoma in situ of the cervix or nonmelanoma skin cancer\*
* Not pregnant\*\*
* Negative pregnancy test\*\*
* Fertile patients must use effective contraception\*\*
* No active infection\*\*
* No medical condition that would interfere with the practice of yoga and meditation\*\* NOTE: \*Patient
NOTE: \*\*Patient and caregiver
PRIOR CONCURRENT THERAPY:
* No other prior or concurrent stress reduction techniques using yoga or meditation\*
* Concurrent standard or investigational chemotherapy, hormonal therapy, immunotherapy, biologic agents, or other complementary and alternative therapies as the primary or adjuvant treatment allowed (patient)
* No concurrent glucocorticoids (caregiver)
* Concurrent dexamethasone allowed provided the daily dose is \< 2 mg/day (patient)
* No concurrent dehydroepiandrosterone sulfate (DHEAS) and/or melatonin supplements\* NOTE: \*Patient and caregiver
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00376818
Study Brief:
Protocol Section:
NCT00376818